Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVNT: Empagliflozin in prediabetes
NCT06828731Phase 1Completed
- Sponsor
- Charles George VA Medical Center
- Start
- Dec 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin in prediabetes (2 arms), sponsored by Charles George VA Medical Center. Primary endpoints: Recruitment at 12 weeks and Retention at 12 weeks. Started Dec 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT06828731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06828731.